Treatment of Women with Epilepsy

Alison M. Pack; Martha J. Morrell

doi:10.1055/s-2002-36648

Seminars in Neurology, Table of Contents

Semin Neurol 2002; 22(3): 289-298
DOI: 10.1055/s-2002-36648

Treatment of Women with Epilepsy

Alison M. Pack, Martha J. Morrell

Department of Neurology, The Neurological Institute, Columbia University, New York, New York

Abstract

ABSTRACT

Epilepsy is equally prevalent in men and women. However, for women there are unique concerns related to hormone effects on seizures and the effects of seizures and antiepileptic drugs (AEDs) on reproductive health. Steroid hormones affect neuronal excitability and seizure frequency. Some AEDs reduce the efficacy of oral contraceptive agents, increasing the probability of unplanned pregnancies. AEDs affect bone density. AEDs may alter reproductive hormones resulting in polycystic-appearing ovaries, anovulatory cycles, and infertility. Seizure frequency may change during pregnancy, seizures may cause pregnancy complications, some AEDs are teratogenic, and many cross into breast milk. The treatment of a woman with epilepsy must consider all these issues.

KEYWORD

Steroid hormones - catamenial seizures - oral contraception - bone health - reproductive health - pregnancy

Full Text

References

REFERENCES

1 Pfaff D W, McEwen B S. Actions of estrogens and progestins on nerve cells. Science . 1983; 219 808-814
2 McEwen B S. Multiple ovarian hormone effects on brain structure and function. J Gend Specif Med . 1998; 1 33-41
3 Woolley C S, Schwartzkroin P A. Hormonal effects on the brain. Epilepsia . 1998; 39 (suppl 8) S2-S8
4 Thomas J, McLean J H. Castration alters susceptibility of male rats to specific seizures. Physiol Behav . 1991; 49 1177-1179
5 Finn D A, Gee K W. The estrous cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid. J Pharmacol Exp Ther . 1994; 271 164-170
6 Wooley D E, Timiras P S. Estrous and circadian periodicity and electroshock convulsions in rats. Am J Physiol . 1962; 202 379-382
7 Wooley D E, Timiras P S. The gonad-brain relationship: effects of female sex hormones and electroshock convulsions in the rat. Endocrinology . 1962; 70 196-209
8 Marcus E M, Watson C W, Goldman P L. Effects of steroids on cerebral electrical activity: epileptogenic effects of conjugated estrogens and related compounds in the cat and rabbit. Arch Neurol . 1966; 15 521-532
9 Stitt S L, Kinnard W J. The effect of certain progestins and estrogens on the threshold of electrically induced seizure patterns. Neurology . 1968; 18 213-216
10 Hom A C, Buterbaugh G G. Estrogen alters the acquisition of seizures kindled by repeated amygdala stimulation or pentylenetetrazol administration in ovariectomized female rats. Epilepsia . 1986; 27 103-108
11 Spiegel E, Wycis H. Anticonvulsant effects of steroids. J Lab Clin Med . 1945; 30 947-953
12 Landgren S, Backstrom T, Kalistratov G. The effect of progesterone on the spontaneous interictal spike evoked by the application of penicillin to the cat's cerebral cortex. J Neurol Sci . 1976; 36 119-133
13 Holmes G L, Kloczko N, Weber D A, Zimmerman A W. Anticonvulsant effect of hormones on seizures in animals. In: Porter RJ, Mattson RH, Ward AM Jr, Dam M, eds. Advances in Epileptology: XVth Epilepsy International Symposium New York: Raven Press 1984: 265-268
14 Tauboll E, Lindstrom S. The effect of progesterone and its metabolite 5-alpha-pregnan-3-alpha-ol-20-one on focal epileptic seizures in the cat's visual cortex in vivo. Epilepsy Res . 1993; 14 17-30
15 Finn D A, Roberts A J, Crabbe J C. Neuroactive steroid sensitivity in withdrawal seizure-prone and resistant mice. Alcoholism Clin Exp Res . 1995; 19 410-415
16 Brann D W, Hendry L B, Mahesh V B. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol . 1995; 52 113-133
17 Herzog A G, Klein P, Ransil B J. Three patterns of catamenial epilepsy. Epilepsia . 1997; 38 1082-1088
18 Mattson R H, Cramer J A, Caldwell B V, Siconolfe B C. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology . 1984; 34 1255-1258
19 Herzog A G. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia . 1991; 32 (suppl 6) 527-533
20 Herzog A G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology . 1995; 45 1660-1662
21 Abbasi F, Krumholz A, Kittner S J, Langenberg P. Effects of menopause on seizures in women with epilepsy. Epilepsia . 1999; 40 205-210
22 Harden C L, Pulver M C, Ravdin L, Jacobs A R. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia . 1999; 40 1402-1407
23 Coulam C B, Annegers J F. Do oral anticonvulsants reduce the efficacy of oral contraceptives?. Epilepsia . 1979; 20 519-526
24 Mattson R H, Cramer J A, Darney P D, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA . 1986; 256 238-240
25 Perrucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther . 1987; 33 139-144
26 McAuley J W, Anderson G D. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet . 2002; 41 559-579
27 Zahn C A, Morrell M J, Collins S D, Collins S D, Labiner D M, Yerby M S. Management issues for women with epilepsy: a review of the literature. American Academy of Neurology Practice Guidelines. Neurology . 1998; 51 949-956
28 American Academy of Neurology. Quality Standards Subcommittee. Practice parameter: management issues for women with epilepsy (summary statement). Neurology . 1998; 51 944-948
29 Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception . 1986; 33 559-565
30 Odlind V, Olsson S E. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception . 1986; 33 257-261
31 Krauss G L, Brandt J, Campbell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology . 1996; 46 1534-1539
32 Morrell M J, Sarto G E, Osborne Shafer P, Borda E A, Herzog A, Callanan M. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med . 2000; 9 959-965
33 Chang S, Ahn C. Effects of antiepileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev . 1994; 16 382-385
34 Valimaki M, Tiihonen M, Laitinen K. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res . 1994; 9 631-637
35 Sheth R, Wesolowski C, Jacob J. Effect of carbamazepine and valproate on bone mineral density. J Pediatr . 1996; 127 256-262
36 Cummings S R, Nevitt M C, Browner W S. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med . 1995; 332 767-773
37 Bogliun G, Beghi E, Crespi V, Delodovick L, d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand . 1986; 74 284-288
38 Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med . 1986; 59 569-577
39 Takeshita N, Seino Y, Ishida H. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int . 1989; 44 80-85
40 Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol . 2000; 47 385-388
41 Sato Y, Kondo I, Ishida S. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology . 2001; 57 445-449
42 Koch H V, Kraft D, von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia . 1972; 13 829-834
43 Kruse K, Suss A, Busse M, Schneider P. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr . 1987; 111 57-63
44 Weinstein R S, Bryce G F, Sappington L J. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab . 1984; 58 1003-1009
45 Vernillo A T, Rifkin B R, Hauschka P V. Phenytoin affects osteoblastic secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone . 1990; 11 309-312
46 Dansky L V, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia . 1980; 21 261-271
47 Webber M P, Hauser W A, Ottman R, Annegers J F. Fertility in persons with epilepsy:1935-1974. Epilepsia . 1986; 27 746-752
48 Schupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biologic influence. Epilepsia . 1994; 35 750-756
49 Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia . 1996; 37 833-840
50 Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet . 1998; 352 1970-1973
51 Herzog A G, Seibel M M, Schomer D L, Vaitukaitis J L, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol . 1986; 43 341-346
52 Meo R, Bilo L, Nappi C. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure . 1993; 2 241-252
53 Dana-Haeri J, Trimble M R, Oxley J. Prolactin and gonadotrophin changes following generalized and partial seizures. J Neurol Neurosurg Psychiatry . 1983; 46 331-335
54 Sperling M R, Pritchard P B, Engel J, Daniel C, Sagel J. Prolactin in partial epilepsy: an indicator of limbic seizures. Ann Neurol . 1986; 20 716-722
55 Bilo L, Meo R, Valentino R, Buscaino G A, Straino S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril . 1991; 55 705-711
56 Drislane F W, Coleman A E, Schomer D L. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology . 1994; 44 306-310
57 Morrell M J, Guidice L, Flynn K L. Predictors of ovulatory failure in women with epilepsy. Ann Neurol . 2002; 52 704-711
58 Isojarvi J IT, Rattya J, Myllyla V V. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol . 1998; 43 446-451
59 Morrell M J, Flynn K L, Seale C G. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectrums . 2001; 6 771-786
60 Morrell M J. Sexuality in epilepsy. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook New York: Lippincott-Raven 1997: 2021-2026
61 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab . 1998; 83 3078-3082
62 Ben-Shlomo I, Franks S, Adashi E Y. The polycystic ovary syndrome: nature or nurture?. Fertil Steril . 1995; 63 953-954
63 Lobo R A. A disorder without identity: "HCA," "PCO," "PCOD," "PCOS," "SLS." What are we to call it?!. Fertil Steril . 1995; 63 1158-1160
64 Clayton R N, Ogden V, Hodgkinson J. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?. Clin Endocrinol (Oxf) . 1992; 37 127-134
65 Isojarvi J IT, Laatikainen T J, Pakarinen A J, Juntunen K TS, Myllyla V V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med . 1993; 329 1383-1388
66 Biton V, Mirza W, Montouris G, Vuong A, Hammer A E, Barrett P S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology . 2001; 56 172-177
67 Morrell M J, Guldner G T. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia . 1996; 37 1204-1210
68 Dana-Haeri J, Oxley J. Reduction of free testosterone by antiepileptic drugs. Br Med J . 1982; 284 85-86
69 Luhdorf K. Endocrine function and antiepileptic treatment. Acta Neurol Scand . 1983; 67 (suppl 94) 15-19
70 Mattson R H, Cramer J A, Collins J F. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med . 1985; 313 145-151
71 Beastall G H, Cowan R A, Gray J MB, Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J . 1985; 30 101-105
72 Fenwick P BC, Mercer C, Grant R. Nocturnal penile tumescence and serum testosterone levels. Arch Sex Behav . 1986; 15 13-21
73 Fisher R S, Vickrey B G, Gibson P. The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions. Epilepsy Res . 2000; 41 39-51
74 Schmidt D, Beck-Mannagetta G, Janz D, Koch S. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Dam M, Richens A, eds. Epilepsy, Pregnancy and the Child New York: Raven Press 1982: 39-49
75 Hauser W A, Hesdorffer D C. Risk factors. In: Hauser WA, Hesdorffer DC, eds. Epilepsy: Frequency, Causes and Consequences New York: Demos 1990: 53-100
76 Yerby M, Morrell M J. Efficacy, safety and tolerability of zonisamide in women. Sexual dysfunction and hormonal abnormalities in women with epilepsy. Epilepsia . 2000; 41 (suppl 7) 199
77 Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for spontaneous abortion. Epilepsia . 1997; 38 824-829
78 Steegers-Theunissen R PM, Renier W O, Borm G F. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multicentre prospective study. Epilepsy Res . 1994; 18 261-269
79 Teramo K, Hiilesmaa V, Brady A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinatal Med . 1979; 7 3-6
80 Gaily E, Granstrom M L. Minor anomalies in children of mothers with epilepsy. Neurology . 1992; 42 (suppl 5) 128-131
81 Annegers J F, Hauser W A, Elveback L R, Anderson V E, Kurland L T. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol . 1978; 7 241-247
82 Friis M L. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand . 1989; 79 433-459
83 Koch S, Loesche G, Jager-Roman E. Major birth malformations and antiepileptic drugs. Neurology . 1992; 42 (suppl 5) 83-88
84 Rosa F W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med . 1991; 324 674-677
85 Omtzigt J GC, Los F J, Grobee D E. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology . 1992; 42 (suppl 5) 119-125
86 Holmes L B, Harvey E A, Coull B A. The teratogenicity of anticonvulsant drugs. N Engl J Med . 2001; 344 1132-1138
87 Gaily E, Kantola-Sorsa E, Granstrom M L. Intelligence of children of epileptic mothers. J Pediatr . 1988; 113 677-684
88 Koch S, Titze K, Zimmerman R B, Scroder M, Lehmkuhl U, Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia . 1999; 40 1237-1243
89 Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry . 2001; 70 15-21
90 Finnell R H, Buehler B A, Kerr B M, Ager P L, Levy R H. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology . 1992; 42 25-31
91 Miranda A F, Wiley M J, Wells P G. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthione sulfoximine in murine embryo culture. Toxicol Appl Pharmacol . 1994; 124 230-241
92 Buehler B A, Delimont D, Van Waes M, Finnell R H. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med . 1990; 322 1567-1572
93 Finnell R H. Genetic differences in susceptibility to anticonvulsant drug induced developmental defects. Pharmacol Toxicol . 1991; 69 223-227
94 Strickler S M, Dansky L V, Miller M A, Seni M H, Andermann E, Spielberg S P. Genetic predisposition to phenytoin-induced birth defects. Lancet . 1985; 2 746-749
95 Nau H, Tzimas G, Mondry M, Plum C, Spohr H L. Antiepileptic drugs alter endogenous retinoid concentration: a possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci . 1995; 57 53-60
96 Tomson T, Lindbom U, Sundqvist A, Berg A. Red cell folate levels in pregnant epileptic women. Eur J Clin Pharmacol . 1995; 48 305-308
97 Laurence K M, James N, Miller M H, Tennant G B, Campbell H. Double-blind, randomized controlled trial of folate treatment before conception to prevent the recurrence of neural tube defects. Br Med J . 1981; 282 1509-1511
98 Dansky L, Andermann E, Roseblatt D, Sherwin A L, Andermann F. Anticonvulsants, folate levels and pregnancy outcome. Ann Neurol . 1987; 21 176-182
99 Yates J RW, Ferguson-Smith M A, Shenkin A, Guzman-Rodriguez R, White M, Clark B J. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects?. Clin Genet . 1987; 31 279-287
100 Mulinare J, Corder J F, Erickson J D. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA . 1988; 260 3141-3145
101 Werler M M, Shapiro S, Mitchell A A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA . 1993; 269 1257-1261
102 Milunsky A, Jick H, Jick S S. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA . 1988; 262 2847-2852
103 Daly L E, Kirke P N, Molloy A, Weir D G, Scott J M. Folate levels and neural tube defects: implications for treatment. JAMA . 1995; 274 1698-1702
104 Gordon N. Folate metabolism and neural tube defects. Brain Dev . 1995; 17 307-311
105 Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep . 1992; 41 1-7
106 Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res . 1991; 8 75-78
107 Oguni M, Dansky L, Andermann E, Sherwin A, Andermann F. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev . 1992; 14 371-380
108 Hernandez-Diaz S, Werler M M, Walker A M. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med . 2000; 343 1608-1614
109 Craig J, Morrison P, Morrow J. Failure of periconceptional folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure . 1999; 8 253-254
110 Seizure disorders in pregnancy. American College of Obstetric and Gynecologic Physicians Educational Bulletin . 1996; 231 1-13
111 Van Allen M, Fraser F C, Dallaire L. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Can Med Assoc J . 1993; 149 1239-1243
112 Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy. Guidelines for the care of women of childbearing age with epilepsy. Epilepsia . 1993; 34 588-589
113 Thorp J A, Gaston L, Caspers D R, Pal M L. Current concepts and controversies in the use of vitamin K. Drugs . 1995; 49 376-387
114 American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics . 1994; 93 137-150